GlassScriptPhysician profile
Charles L Glace
NPI 1730133596
$5,397.21
in general payments reported to CMS, 2019-2025
39 companies · $38.55 in 2025
The $38.55 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $1,463 · 2021: $1,267 · 2022: $848 · 2023: $645 · 2024: $147 · 2025: $38.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $584.06 | 2019-2023 | Livalo, Seglentis |
| Amarin Pharma, INC. | $533.64 | 2019-2023 | |
| Abbvie INC. | $502.00 | 2019-2023 | |
| Pfizer INC. | $419.14 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $383.19 | 2019-2024 | Farxiga, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $342.68 | 2019-2024 | Trintellix |
| Novo Nordisk INC | $319.85 | 2019-2022 | |
| Allergan, INC. | $264.40 | 2020 | |
| Sanofi-Aventis U.S. LLC | $259.48 | 2019-2022 | |
| Lilly USA, LLC | $233.80 | 2019-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.73 | 2019-2021 | |
| Amgen INC. | $202.56 | 2019-2023 | Repatha, Otezla |
| Antares Pharma, INC. | $145.30 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Abbott Laboratories | $142.96 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.28 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Glace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.